Order Online! Now! Get your $50 coupon for online order.
Order Online! Now! Get your $50 coupon for online order.
Our limited edition HOLIDAYS LLAMA is here! Place any order now to recieve one!
Earn Loyalty Rewards! Up to $155 Amazon Gift Card
Time Limited Offer: Welcome Gift for New Customers !
Time Limited Offer: Welcome Gift for New Customers !
Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
MEK-M52H9 | Mouse | Mouse MERTK / Mer Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
|
MEK-H5253 | Human | Human MERTK / Mer Protein, Fc Tag | ![]() |
![]() ![]() |
![]() ![]() |
MEK-C5253 | Cynomolgus | Cynomolgus MERTK / Mer Protein, Fc Tag (MALS verified) | ![]() |
![]() ![]() |
|
MEK-M5253 | Mouse | Mouse MERTK / Mer Protein, Fc Tag (MALS verified) | ![]() |
![]() ![]() |
|
MEK-H52H6 | Human | Human MERTK / Mer Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
Human MERTK, His Tag (Cat. No. MEK-H52H6) immobilized on CM5 Chip can bind Human GAS6, His Tag (Cat. No. GA6-H5249) with an affinity constant of 50.9 nM as determined in SPR assay (Biacore 8K) (Routinely tested).
The purity of Mouse MERTK, His Tag (Cat. No. MEK-M52H9) is more than 90% and the molecular weight of this protein is around 70-95 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Cabozantinib S-malate | XL-184; BMS-907351 | Approved | Exelixis Inc | Cometriq, Cabometyx | United States | Thyroid Neoplasms; Carcinoma, Neuroendocrine | Exelixis Inc | 2012-11-29 | Sarcoma, Ewing; Thyroid Neoplasms; Thymus Neoplasms; Gliosarcoma; Colorectal Neoplasms; Peritoneal Neoplasms; Bile Duct Neoplasms; Hepatic Insufficiency; Astrocytoma; Breast Neoplasms; Lymphoma; Osteosarcoma; Carcinoma, Adenosquamous; Adenocarcinoma, Clear Cell; Sarcoma, Clear Cell; Medullary thyroid cancer (MTC); Cholangiocarcinoma; Prostatic Neoplasms; Neurofibroma, Plexiform; Urethral Neoplasms; Carcinoma, Neuroendocrine; Meningioma; Carcinoma, Non-Small-Cell Lung; Paraganglioma; Melanoma; Carcinoma, Endometrioid; Thyroid Cancer, Papillary; Adenocarcinoma; Neoplasms, Germ Cell and Embryonal; Carcinoma, Hepatocellular; Neuroblastoma; Glioma; Leukemia, Myeloid, Acute; Carcinoma, Squamous Cell; Endometrial Neoplasms; Lung Neoplasms; Sarcoma, Alveolar Soft Part; Uterine Neoplasms; Fallopian Tube Neoplasms; Carcinoid Tumor; Neurofibromatoses; Seminoma; Carcinoma, Transitional Cell; Glioblastoma; Rejection of liver transplantation; Carcinoma, Merkel Cell; Hepatoblastoma; Pain; Pheochromocytoma; Neoplasms; Carcin | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
INCB-081776 | INCB-81776; INCB-081776 | Phase 1 Clinical | Incyte Corp | Solid tumours; Neoplasms | Details |
MRX-2843 | MRX-2843; UNC-2025; UNC-2371 | Phase 2 Clinical | Meryx Inc, University Of North Carolina At Chapel Hill, University Of Colorado At Denver | Leukemia; Solid tumours; Neoplasms; Pathologic Processes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Lung Neoplasms; Neoplastic Processes; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
Merestinib | LY-2801653; 5OGS5K699E | Phase 2 Clinical | Eli Lilly And Company | Solid tumours; Biliary Tract Neoplasms; Skin Melanoma; Bone metastases; Neoplasms; Pancreatic Neoplasms; Microsatellite instability-high cancer; Lymphoma, Mantle-Cell; Cholangiocarcinoma; Breast Neoplasms; Colorectal Neoplasms; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Gallbladder Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
Zanzalintinib | XL-092 | Phase 3 Clinical | Exelixis Inc | Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
Sitravatinib | MG-91516; MGCD-516; IND-155305; MG-516 | Phase 3 Clinical | Mirati Therapeutics Inc | Breast Neoplasms; Gastrointestinal Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Lung Neoplasms; Esophageal Squamous Cell Carcinoma; Mouth Neoplasms; Carcinoma, Squamous Cell; Hepatic Insufficiency; Ureteral Neoplasms; Solid tumours; Liposarcoma; Lung Diseases; Uveal melanoma; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Neoplasms; Carcinoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Kidney Neoplasms; Biliary Tract Neoplasms | Details |
NPS-1034 | HOPE-777; KDDF-201111-02 | Neopharma Ltd | Details |
This web search service is supported by Google Inc.